Microcarrier Cell Culture Patents: Leaders & White Space 2026
Microcarrier Cell Culture and Perfusion Culture Patents
Concentrated at the top. The five leading assignees together hold 42.0% of all 336 records in scope, and the leader alone accounts for 46 records. Annual filings rose from 6 records in 2017 to a peak of 36 in 2022, then declined to 6 by 2024 — a -68% move from the 19 filed in 2021. Treat 2025 and 2026 figures as incomplete rather than as confirmation the field is shrinking.
- 1WILSON WOLF MANUFACTURING CORP46
- 2GENZYME CORP29
- 3CELLINO BIOTECH INC26
- 4ARES TRADING SA20
- 5SCHERING CORP20
See the full microcarrier cell culture perfusion culture analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in microcarrier and perfusion cell culture?
The dataset ranks 95 assignees, and a single company leads with 46 records against 336 total in scope. The next four ranked assignees combine with the leader for 42.0% of all records, indicating a concentrated top tier. Beyond the top ten — who together hold 61.9% of records — filing activity drops sharply into a long tail of companies with only a handful of filings each.
Is patent filing in this field growing or slowing down?
Filing rose from 6 records in 2017 to a peak of 36 in 2022, then fell to 6 by 2024, a -68% change from the 19 filed in 2021. However, publication typically lags filing by around 18 months, so the 2025 and 2026 figures in this dataset are still incomplete and should not be read as confirmation of a real slowdown. A clearer read on the current trajectory will only be available once those years finish publishing.
What technology areas dominate the claims?
C12N, covering microorganisms and genetic engineering, appears on 83.9% of the 336 records, and C12M, covering bioreactors and enzyme apparatus, appears on 58.0% — meaning most filings combine a biological composition claim with hardware or process-control claims. Smaller but notable shares sit in A61K medicinal preparations (14.0%), C07K peptides and proteins (9.8%), and G01N material testing (9.2%). These figures overlap because a single record can carry more than one IPC classification.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Microcarrier Cell Culture Perfusion Culture covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.